Liquid Cartilage and ChondroFiller are the same treatment

If you have encountered both names whilst researching cartilage treatment, they refer to a single product. Liquid Cartilage™ is a commercial brand name coined by MSK Doctors and London Cartilage Clinic to give patients a more accessible label for ChondroFiller™ — the CE-marked Class III medical device that underpins the treatment. The clinic's own FAQ states this plainly: 'The product currently used is ChondroFiller™, a CE-marked Class 3 medical implant.'

ChondroFiller™ is a registered trademark of Meidrix Biomedicals GmbH, a German manufacturer. The 'German gel' description that circulates in patient forums is a straightforward reflection of that origin: the product is made in Germany, and the earliest published clinical trials were carried out in Germany under Prof. Ulrich Schneider at Arthro Nova Clinic GmbH in Ringsee. London Cartilage Clinic's contribution was introducing an ultrasound-guided injectable pathway for this already CE-marked device — not developing a separate product.

What ChondroFiller actually is

The product itself is a collagen scaffold, not a lubricant or filler in the conventional sense. ChondroFiller® is an acellular, two-component hydrogel made from Type I collagen derived from veterinary-monitored murine sources; the acellular processing removes cellular material before it reaches the patient, which is standard practice for collagen-based medical implants of this class. When the two components combine at the defect site, they gel within minutes into a three-dimensional matrix — a structural framework for the body's own cells, not simply a coating applied to the joint surface.

Regulatory status matters here. ChondroFiller® carries CE marking as a Class III medical device — the highest tier under EU Medical Device Regulation. Class III does not signal greater danger; it signals greater scrutiny. A device in this category contacts living tissue directly and must clear the most rigorous pre-market evaluation available under European law, including clinical data review by an independent notified body, before it can be used in any patient. For someone weighing their options, that designation is a marker of regulatory due diligence, not a warning flag.

How the collagen scaffold works inside the joint

Once the collagen solution meets the defect environment, something specific happens: the two components polymerise within minutes into a stable, three-dimensional scaffold that sits within the damaged area rather than simply coating it. That scaffold then does something a lubricant injection or a permanent hydrogel filler cannot — it actively recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, drawing them into the matrix through a chemotactic signalling process. Those migrating cells differentiate into chondrocytes and, over subsequent months, progressively replace the degrading scaffold with native-like cartilage matrix. This is the mechanism known as acellular matrix-induced chondrogenesis — meaning the scaffold itself drives tissue formation by recruiting the body's own cells, with no donor cells introduced.

Early mechanistic support for this cell-recruitment effect comes from a 2025 ex vivo human osteochondral explant model, which recorded a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14, consistent with active cell ingrowth; co-treatment with mesenchymal stem cells further augmented glycosaminoglycan and collagen deposition. This is preclinical evidence, not proof of clinical regrowth, but it offers a quantified window into the biology the scaffold is designed to harness.

The contrast with other injectable options is worth stating plainly in one sentence: where a permanent hydrogel such as Arthrosamid occupies joint space mechanically, ChondroFiller is intended to promote endogenous repair and then biodegrade as newly formed tissue takes its place.

Which patients and joints are suitable

The single most important selection criterion is defect type. ChondroFiller may be suitable for focal cartilage lesions — areas of Grade III or IV damage with defined margins — where enough healthy surrounding tissue and subchondral bone remain to supply progenitor cells to the scaffold. Diffuse degenerative joint disease is a different clinical picture, and the distinction matters more than joint location or age alone.

Patient selection data make this concrete. In a 2021 hip cohort of 26 patients treated for acetabular lesions greater than 2 cm², 17 of the 21 followed up at three to five years achieved good or excellent results. The exception was telling: patients with pre-existing osteoarthritis at Tönnis grade 2–3 had poor outcomes in the same group. A scaffold that relies on the body's own repair machinery needs viable tissue to recruit from; where that tissue is already extensively compromised by OA, the biological conditions for chondrogenesis are absent.

Published evidence spans knee, hip, ankle, shoulder, elbow, wrist, and foot — a range that reflects the product's adaptability to differently sized joints, though dose and placement precision vary considerably. Wrist applications, for instance, require as little as 0.2–0.3 mL, and overfilling in small joints has been shown to produce fibrous tissue rather than hyaline-like repair. Image-guided placement is therefore not simply a procedural convenience; it is part of what makes suitability conditional on technique as much as anatomy.

For patients who do meet focal-defect criteria, published knee series suggest that functional gains tend to consolidate between six and twelve months rather than continuing to accumulate indefinitely — a useful reference point when forming realistic expectations rather than a ceiling on improvement. The key dividing line remains focal versus diffuse: where the damage is contained, the scaffold has a defined structural role; where it is not, the biology is working against the treatment.

What the clinical evidence shows

In the earliest controlled trial, published in 2016 by Prof. Ulrich Schneider at Arthro Nova Clinic GmbH in Ringsee, Germany, 13 patients treated with ChondroFiller showed statistically significant IKDC score improvements at three, six, and twelve months compared with baseline (p<0.05); the comparator group of ten patients treated with microfracture did not reach the same consistent trajectory. MRI confirmed scaffold integration and progressive cartilage maturation over time, and no adverse events were reported across the ChondroFiller cohort.

A 2021 hip cohort of 26 patients with acetabular lesions greater than 2 cm² extended the joint range. At three to five years, 17 of the 21 patients available for follow-up had achieved good or excellent results. The exception — poor outcomes in those with Tönnis grade 2–3 pre-existing osteoarthritis — reinforces the focal-defect selection criteria described earlier in this article.

A Bulgarian knee series published in 2024 enrolled 17 patients with a mean age of 31. Lysholm and IKDC scores improved significantly at three and six months (p<0.05), with no statistically significant further change between six and twelve months — a plateau that is clinically useful to know rather than a cause for concern.

The most recent joint-specific data comes from a 2025 wrist study of 59 patients with distal radius fractures, 25 of whom received ChondroFiller. Cartilage quality scores were significantly better than controls (Outerbridge median 1.5 vs 3, p=0.006; ICRS grade 1 vs 3, p=0.002), with fibrous tissue appearing only in defects that had been overfilled.

Across these peer-reviewed series, the manufacturer's own Clinical Evaluation Report (CER v09, April 2025) — which should be read as supportive context rather than independent evidence — reports a consistent improvement of approximately 30 IKDC points over one year, MOCART imaging scores between 70 and 87, and a product complaint rate of around 0.06%. The evidence base is encouraging, but the study populations remain small and long-term randomised controlled data are still maturing.

How treatment is delivered and what it costs

ChondroFiller is delivered at London Cartilage Clinic as an outpatient appointment, not a theatre procedure. In a single clinic visit, the collagen scaffold is placed under real-time ultrasound guidance into the cartilage defect with no general anaesthetic and no surgical incision. The standard dose for a knee or hip application is 2.3 mL; smaller joints require considerably less. Image guidance allows the treating clinician to position the material precisely — a practical detail that also matters for the biology of what follows.

Professor Paul Y.F. Lee, consultant at London Cartilage Clinic on Harley Street, introduced this ultrasound-guided injectable pathway to the UK. For assessment and appointment enquiries, the clinic can be reached at londoncartilage.com.

Treatment is self-funded private care. It is not available through the NHS and is not covered by standard private medical insurance. Guide pricing for a ChondroFiller injection starts at approximately £3,000, which typically covers the consultation, imaging, the product itself, antibiotic cover, and a follow-up appointment. Combination protocols that incorporate MSC cell therapy can reach up to £11,000. Costs vary by joint and protocol and should be confirmed directly with the clinic before committing to treatment.

For patients who have previously considered or been advised towards surgical options, the contrast in the appointment itself is worth noting: no overnight admission, no wound to manage, and a recovery shaped by the pace of cartilage repair rather than by healing from an incision.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
3. [3] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Implantation of ChondroFiller Liquid® as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
5. [5] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z